Latest News and Press Releases

Autolus announces business updates and an overview of 2025 milestones.

Wilmington, Delaware, United States, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The acute lymphoblastic leukemia market was estimated to have acquired US$ 2.2 billion in...

Wilmington, Delaware, United States, Aug. 04, 2023 (GLOBE NEWSWIRE) -- The global acute lymphoblastic leukemia market is projected to flourish at a CAGR of 7.6% from 2022 to 2031. As per the report...

- Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL - Complete responses observed in patients with CD19 negative disease - No antigen negative...

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track...

LONDON, March 31, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Nicklaus Children's Hospital is one of only a few pediatric hospitals in Florida, and the only one in South Florida, to offer the latest immune cell...

Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm...

LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...

AUTO1 shows 87% MRD negative complete response in adult patients with r/r ALL, with no severe cytokine release syndrome   Data presented at 61st American Society of Hematology Annual Meeting form...